Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
Two key developments in US oncology signal faster progress: a new standard therapy for aggressive colorectal cancer and …
The biotech sector saw compelling developments from funding milestones to shifts in trial regulations and rising promise in …
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
New clinical data presented at the European Lung Cancer Congress show PDC*line Pharma’s vaccine potential to boost immune …
A wave of major financings and collaborations on February 25 signals renewed investor confidence in biotech, with giants …
February 2025 sees a surge in large-scale biotech investments—from Eikon’s massive Series D to critical autoimmune and oncology …
The FDA has approved GSK’s MenABCWY vaccine—the first pentavalent conjugate capable of protecting against five key meningococcal serogroups—marking …
Already a subscriber? Log in